WordNet

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. シクロスポリンおよびタクロリムスの腎毒性 cyclosporine and tacrolimus nephrotoxicity
2. シクロスポリンおよびタクロリムスの薬理作用および副作用 pharmacology and side effects of cyclosporine and tacrolimus
3. 肺移植後の免疫抑制の維持 maintenance immunosuppression following lung transplantation
4. 成人腎移植レシピエントの診療の概要 overview of care of the adult kidney transplant recipient
5. 成人の腎移植における免疫抑制維持療法 maintenance immunosuppressive therapy in renal transplantation in adults

Guada M1, Beloqui A2, Alhouayek M3, Muccioli GG3, Dios-Viéitez Mdel C4, Préat V2, Blanco-Prieto MJ5.
International journal of pharmaceutics.Int J Pharm.2016 Apr 30;503(1-2):196-8. doi: 10.1016/j.ijpharm.2016.03.012. Epub 2016 Mar 10.
Cyclosporine A (CsA) is a well-known immunosuppressive agent used as rescue therapy in severe steroid-refractory ulcerative colitis (UC). However, toxicity issues associated with CsA when administered in its commercially available formulations have been reported in clinical practice. Since nanotechn
PMID 26972380

Cobicistat Significantly Increases Tacrolimus Serum Concentrations in a Renal Transplant Recipient with Human Immunodeficiency Virus Infection.

Han Z1, Kane BM1, Petty LA2, Josephson MA3, Sutor J4, Pursell KJ2.
Pharmacotherapy.Pharmacotherapy.2016 Apr 3. doi: 10.1002/phar.1752. [Epub ahead of print]
Cobicistat is a pharmacokinetic booster in several fixed-dose combination products for treatment of human immunodeficiency virus (HIV) infection. As a potent inhibitor of cytochrome P450 (CYP) 3A enzymes, significant drug-drug interactions are expected between cobicistat and medications that are met
PMID 27041642

Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation.

Guada M1, Lana H2, Gil AG3, Dios-Viéitez Mdel C2, Blanco-Prieto MJ4.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V.Eur J Pharm Biopharm.2016 Apr;101:112-8. doi: 10.1016/j.ejpb.2016.01.011. Epub 2016 Feb 10.
The pharmacodynamic effect and the safety of cyclosporine A lipid nanoparticles (CsA LN) for oral administration were investigated using Sandimmune Neoral® as reference. First, the biocompatibility of the unloaded LN on Caco-2 cells was demonstrated. The pharmacodynamic response and blood levels of
PMID 26877154

内藤隆文
YAKUGAKU ZASSHI 130(12), 1695-1700, 2010
… A fixed dosing of MMF often causes bone marrow toxicity or cytomegalovirus antigenemia under the optimal dosing of calcineurin inhibitors. … In addition, concomitant metal cation decreased MPA concentration in patients receiving tacrolimus but not cyclosporine. … Renal clearance of MPA was higher in cyclosporine- than tacrolimus-treated patients. …
NAID 130000451729

Cyclosporin therapy for acquired aplastic anemia: Predictive factors for the response and long-term prognosis

Yamazaki Hirohito,Sugimori Chiharu,Chuhjo Tatsuya,Nakao Shinji
International journal of hematology 85(3), 186-190, 2007-04-15
… Although cyclosporine (CsA) is a key drug in the treatment of acquired aplastic anemia (AA), the role of single-agent therapy with CsA remains unclear. … Given its low toxicity and because the effectiveness of CsA can be judged within 2 months of therapy, CsA may be the first drug of choice at outpatient clinics for AA patients not requiring transfusions. …
NAID 10019488749